Health Economics›B-cell acute lymphoblastic leukemia›Extended induction therapy

Extended induction therapy

B-cell acute lymphoblastic leukemia · 1 regimen

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Daunorubicin, Pegaspargase, Vincristine, Prednisone Variant #11 Partial	—	R 2 355	42d	—	—	~1	~R 2 355 indirect	—

1 of 1 regimen shown